Fang-Chia Chang

Prof. Fang-Chia Chang

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Neuropharmacology
Verified
Journal Article
Closed access
YHYi-Tse Hsiao
Yi-Tse Hsiao
PYPei-Lu Yi
Pei-Lu Yi
CLChia-Ling Li
Chia-Ling Li
Fang-Chia ChangFang-Chia Chang
Fang-Chia Chang

1 July 2001 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
Fang-Chia ChangFang-Chia Chang
Fang-Chia Chang
MOMark R Opp
Mark R Opp

1 September 2002 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
CTC.H Tsai
C.H Tsai
SLS.K Lo
S.K Lo
LSLai-Chu See
Lai-Chu See
HCH.Z Chen
H.Z Chen
RCR.S Chen
R.S Chen
CLC.S Lu
C.S Lu

1 March 2004 in Journal of Biomedical Science
Verified
Journal Article
Closed access
PDF file
Fang-Chia ChangFang-Chia Chang
Fang-Chia Chang
HTHuei-Yann Tsai
Huei-Yann Tsai
MYMing-Chien Yu
Ming-Chien Yu
PYPei-Lu Yi
Pei-Lu Yi
JLJaung-Geng Lin
Jaung-Geng Lin

1 September 1998 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Closed access
PDF file
Fang-Chia ChangFang-Chia Chang
Fang-Chia Chang
MOMark R. Opp
Mark R. Opp
We have previously hypothesized that corticotropin-releasing hormone (CRH) is involved in the regulation of physiological waking. To further elucidate this role for CRH, we administered intracerebroventricularly into rats two specific CRH-receptor antagonists, α-helical CRH-(9—41) (α-hCRH) or astressin, and determined changes in electroencephalogram-defined waking and sleep. Our results indicate that both of these receptor antagonists reduce the amount of time spent awake in a dose-related manner when administered before the dark period of the light-dark cycle. However, the time courses for these effects differ between antagonists; effective doses of α-hCRH reduce waking during the first 2 h postinjection, whereas effective doses of astressin reduce waking during postinjection hours 7–12. In contrast to dark-onset administrations, the amount of waking is not altered by either CRH-receptor antagonist when administered before the light period. These results support our hypothesis that CRH contributes to the regulation of physiological waking, since interfering with the binding of CRH to its receptor reduces spontaneous waking.

1 April 2007 in SLEEP
Verified
Journal Article
Open access
PDF file
PYPei-Lu Yi
Pei-Lu Yi
CTChon-Haw Tsai
Chon-Haw Tsai
MLMing-Kuei Lu
Ming-Kuei Lu
HLHsu-Jan Liu
Hsu-Jan Liu
YCYa-Chu Chen
Ya-Chu Chen
Fang-Chia ChangFang-Chia Chang
Fang-Chia Chang
Recently, the pathogenesis of Parkinson disease (PD) has been focused on microglial activation, especially the subsequent increase of cytokines. A body of clinical evidence suggests that sleep is altered in patients with PD; however, there is a lack of understanding of the basic cellular mechanism. This study was designed to elucidate the influence of brain interleukin (IL)-1β on sleep changes, in addition to the dopaminergic and γ-aminobutyric acid (GABA)-ergic systems, in an animal PD model. We employed a long-term subcutaneous infusion of rotenone, a mitochondrial complex-I inhibitor, to induce a parkinsonism-like model in rats. Behavioral tests and tyrosine hydroxylase immunocytochemistry were used for confirmation of PD in this animal model. Pharmacologic agonist and antagonists were administered centrally to test the involvement of dopamine, GABA, and IL-1 in rotenone-induced sleep alteration. Protein expression of cytokines, ie, IL-1β and tumor necrosis factor α (TNF-α), in 5 distinct brain regions was also determined by Western blot and enzyme-linked immunosorbent assay (ELISA). Sleep-recording equipment in the National Taiwan University and China Medical University. Male Sprague-Dawley rats were implanted with electroencephalogram electrodes, a thermistor, and an intracerebroventricular guide cannula. Chronic infusion of rotenone was given by an Alzet minipump implanted subcutaneously on the back of each rat. We found that locomotion activity was reduced, slow-wave sleep (SWS) was increased during the dark (active) phase and decreased during the light (rest) period, and rapid eye movement sleep (REM) was enhanced in the dark period after rotenone treatment. This rotenone PD animal model successfully causes loss of tyrosine hydroxylase-immunopositive neurons in the substantia nigra; induces the events of sleep disturbance, such as excessive daytime sleepiness and insomnia during the nighttime, that are seen in patients with PD; and suppresses locomotion. Our results that intracerebroventricular administration of dopamine and blockade of GABA in the brain have less significant effect on rotenone-induced sleep alteration suggest that the sleep disturbance is not primarily mediated by the disruption of dopaminergic and GABAergic systems in the current PD rat model. The expression of TNF-α was not altered by rotenone. However, the results of enhanced expression of IL-1β in the hypothalamus after rotenone and that of the blockade of sleep alteration, but not the locomotion activity, by intracerebroventricular administration of an IL-1 receptor antagonist implies that increased IL-1β in the hypothalamus mediates sleep alteration, but not the locomotion, in rats with rotenone-induced parkinsonism. These observations suggest that rotenone-induced sleep-wake alteration is dominated by central increase of somnogenic IL-1.